ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,187.67
0.00%
US Tech 100
17,576.00
-0.21%
Dow Jones
39,056.39
0.44%
Brent Oil
83.56
0.84%
Bitcoin
61,533.37
-1.28%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Bioventus Inc (BVS) Quote

Bioventus Inc

Bioventus Inc (BVS)

Bravura Solutions Limited
5.04
-0.08
(-1.56%)
At close: May 08 4:00PM
Delayed by 15 minutes
4.95
-0.17
( -3.32% )
After Hours: 5:44PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
4.95
Bid
4.84
Ask
5.12
Volume
703,117
4.91 Day's Range 5.50
0.00 52 Week Range 0.00
Market Cap
399.786M
Previous Close
5.12
Open
5.40
Last Trade
175
@
4.95
(formt)
Last Trade Time
17:44:00
Financial Volume
$ 3,599,518
VWAP
5.1194
Average Volume (3m)
-
Shares Outstanding
79,165,540
Dividend Yield
-
PE Ratio
-2.56
Earnings Per Share (EPS)
-1.97
Revenue
512.35M
Net Profit
-156.23M

About Bioventus Inc

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, in... Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.bioventus.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Bioventus Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker BVS. The last closing price for Bioventus was $5.12. Over the last year, Bioventus shares have traded in a share price range of $ 0.00 to $ 0.00.

Bioventus currently has 79,165,540 shares outstanding. The market capitalization of Bioventus is $399.79 million. Bioventus has a price to earnings ratio (PE ratio) of -2.56.

BVS Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 07 2024
Edgar (US Regulatory)

Bioventus Reports First Quarter Financial Results

Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic PrioritiesAccelerated First Quarter Revenue Growth by 8.7%, Organic Growth* by...

May 07 2024
GlobeNewswire Inc.

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will...

April 29 2024
GlobeNewswire Inc.

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3%Appointed Rob Claypoole as President and Chief Executive Officer, bringing more than 20 years of leadership experience in...

March 12 2024
GlobeNewswire Inc.

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

DURHAM, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will...

March 04 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 06 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

January 22 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CPOPPop Culture Group Company Ltd
$ 2.48
(45.88%)
274.34k
SEZLSezzle Inc
$ 53.00
(18.46%)
4.39k
ZIMVZimVie Inc
$ 18.00
(17.04%)
91.33k
STKLSunOpta Inc
$ 6.49
(14.87%)
29.98k
APPApplovin Corporation
$ 83.40
(12.70%)
875.83k
ETAOETAO International Company Ltd
$ 1.28
(-32.98%)
180.31k
EMKREMCORE Corporation
$ 2.0344
(-29.85%)
342.76k
CDLXCardlytics Inc
$ 10.61
(-27.33%)
444.61k
CTMXCytomX Therapeutics Inc
$ 3.4108
(-18.60%)
20.78M
EXASEXACT Sciences Corporation
$ 48.45
(-18.54%)
288.82k
CTMXCytomX Therapeutics Inc
$ 3.4108
(-18.60%)
20.78M
HOODRobinhood Markets Inc
$ 18.55
(3.92%)
6.33M
CYNCYNGN Inc
$ 0.0909
(-12.26%)
4M
ARMARM Holdings PLC
$ 98.47
(-7.17%)
3.82M
LCIDLucid Group Inc
$ 2.705
(-0.18%)
3.67M

BVS Discussion

View Posts
tw0122 tw0122 1 day ago
Durolane like it .. older news ..Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

Source: GlobeNewswire Inc.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.
OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE, help manage knee OA pain.

“We are pleased DUROLANE is among the preferred options available to both Aetna™ Medicare Advantage members and physicians,” said Anthony Doyle, General Manager, Pain Treatments and Restorative Therapies for Bioventus. “Both now have access to a safe HA product that is proven to provide relief from knee OA pain.”

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

👍️0
TheFinalCD TheFinalCD 1 day ago
$BVS - Bioventus GAAP EPS of -$0.07 beats by $0.18, revenue of $129.45M beats by $11.07M https://t.co/IGk1Zy2r5X— Seeking Alpha Market News (@MarketCurrents) May 7, 2024
👍️0
Monksdream Monksdream 3 weeks ago
BVS under $5

👍️0

Your Recent History

NASDAQ
BVS
Bioventus
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved